

Eurogin Roadmap 2015: How has HPV knowledge changed our practice: Vaccines

Julia M.L. Brotherton^{1,2}, Mark Jit^{3,4}, Patti E. Gravitt⁵, Marc Brisson⁶, Aimée R. Kreimer⁷, Sara I. Pai⁸, Carole Fakhry⁹, Joseph Monsonego¹⁰ and Silvia Franceschi¹¹

¹ National HPV Vaccination Program Register, VCS Registries, East Melbourne, Vic, Australia

² School of Population and Global Health, University of Melbourne, Vic, Australia

³ Modelling and Economics Unit, Public Health England, London, United Kingdom

⁴ Department of Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, United Kingdom

⁵ Department of Pathology, University of New Mexico Health Sciences Center, Albuquerque, NM

⁶ Département de Médecine Sociale et Préventive, Université Laval, Québec, QC, Canada

⁷ Infections & Immunoepidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD

⁸ Department of Surgery, Harvard Medical School, Massachusetts General Hospital, Boston, MA

⁹ Department of Otolaryngology Head and Neck Surgery, Johns Hopkins School of Medicine, Johns Hopkins Outpatient Center, Baltimore, MD

¹⁰ Institut du Col, 174 Rue de Courcelles, Paris, 75017, France

¹¹ International Agency for Research on Cancer, 69372 Lyon cedex 08, France

This review is one of two complementary reviews that have been prepared in the framework of the Eurogin Roadmap 2015 to evaluate how knowledge about HPV is changing practices in HPV infection and disease control through vaccination and screening. In this review of HPV vaccine knowledge, we present the most significant findings of the past year which have contributed to our knowledge of the two HPV prophylactic vaccines currently in widespread use and about the recently licensed nonavalent HPV vaccine. Whereas anal cancer is dealt with in the companion mini-review on screening, we also review here the rapidly evolving evidence regarding HPV-associated head and neck cancer and priority research areas.

Key words: HPV, vaccine, cervical cancer, oropharyngeal cancer

Abbreviations: AIN: anal intraepithelial neoplasia; CIN: cervical intraepithelial neoplasia; EU: European union; HIC: high income country; HNSCC: head neck squamous cell cancer; HPV: human papillomavirus; LIC: low income country; MIC: middle income country; NPCR: National Program of Cancer Registries; OPCs: oropharyngeal cancers; PD1: programmed cell death-1; PIN: penile intraepithelial neoplasia; SEER: Surveillance Epidemiology and End Result Program; VIA: visual inspection with acetic acid; WHO: World Health Organization

Conflicts of interest: JMLB has been an investigator on investigator designed unrestricted epidemiological research grants partially funded through bioCSL/Merck but has received no personal financial benefits. In the past 3 years, MB received an unrestricted grant from Merck Frosst related to Zoster burden of illness (no grants ongoing). JM reports having received honorarium as a member of the scientific advisory board of Sanofi Pasteur MSD, Merck, Roche Diagnostics, Gen-Probe and Gentical and compensation from Merck and Glaxo Smith Kline to conduct vaccine trials.

DOI: 10.1002/ijc.30063

History: Received 16 Sep 2015; Accepted 11 Feb 2016; Online 24 Feb 2016

Correspondence to: Assoc Prof Julia Brotherton, PO Box 310, East Melbourne, 8002, Victoria Australia, Tel.: +61 3 9250 0377, Fax: +61 3 8417 6835, E-mail: jbrother@vcs.org.au

Current Knowledge About the Efficacy and Safety of Prophylactic HPV Vaccines

It is now ten years since the first prophylactic HPV vaccine was licensed for use following extensive clinical trials. At the time of licensing, the vaccines were known to be highly efficacious in HPV-naïve individuals at preventing vaccine-type HPV infection and type specific cervical disease and, for the quadrivalent vaccine, genital warts and vulvar/vaginal intraepithelial lesions. We have now direct evidence that both vaccines provide protection for close to a decade, if not longer. Large sentinel cohorts of young Nordic women and smaller cohorts from the original trials are being closely monitored to detect any loss of protection over time.¹⁻³ Antibody levels elicited after vaccination peak after the third dose and decline (to levels still well above those seen following natural infection) by 24 months and are relatively stable thereafter.⁴ Bivalent HPV vaccination produces higher levels of both vaccine-type antibodies and antibodies that have some cross-protective efficacy against high risk HPV types related to HPV16 and 18 (specifically, types 31, 33, 45, and 51⁵) as compared with the quadrivalent HPV vaccine although long term protection is unknown.⁶ The utilization of differing serological assays complicates the interpretation of 'seropositivity'⁷ and there is as yet no established immune correlate of protection. Since initial licensure, trials of the quadrivalent vaccine in men have also established efficacy against genital warts, penile intraepithelial neoplasia (PIN) and anal

intraepithelial neoplasia (AIN)^{8,9} leading to registration and use of the vaccine in males in some countries.

The safety of the vaccines has continued to be monitored through population-based vaccine safety surveillance systems, studies and follow up of trial participants.^{10–18} The WHO Global Advisory Committee for Vaccine Safety continues to regularly review these data and confirm safety.¹⁹ Failure to achieve high population coverage limits the full potential benefits gained from vaccination, which are observed in countries with successfully implemented vaccine programs.²⁰ A 2015 meta-analysis by Drolet and colleagues of multi-country HPV vaccine effectiveness data demonstrates that significant reductions in HPV infection, genital warts and cervical intraepithelial neoplasia (CIN) are being achieved and that herd protection of males and unvaccinated women is occurring in populations with sufficient coverage of females, *e.g.*, Australia.²⁰ A recent modelling study indicates that including males accelerates the reduction in HPV prevalence and improves the resilience of vaccination programs.²¹

A potentially significant development to improve population coverage was WHO's 2014 endorsement of two dose HPV vaccination schedules for young adolescents, using an interval of at least 6 months.²² This endorsement was partly based on trials comparing immunogenicity in young adolescents of two doses with three doses given to adult women in whom efficacy was established.^{23,24} These studies established non-inferiority of antibody titres out to 36 months (quadrivalent) and 48 months (bivalent) induced by a two dose extended schedule in females aged up to 15 years at first dose. Two dose schedules should reduce costs and may improve coverage depending upon how effectively delivery systems are able to ensure receipt of the second dose given the wider dose spacing. Surveillance of cohorts vaccinated with two doses will be required to ensure protection is maintained.²⁵ Duration of protection is clearly critical to the effectiveness and cost-effectiveness of a two-dose *vs.* three-dose schedule.²⁶ The most recent data available demonstrate non-inferiority of antibody titres induced by bivalent vaccine for young two dose recipients compared with older women out to 5 years.²⁷ In addition, efficacy of not only two doses of bivalent vaccine, but also a single dose, against persistent HPV infection has recently been shown in an analysis of clinical trial data from women intended to receive the three dose schedule.²⁸ This analysis extends the findings from the Costa Rica HPV Vaccine Trial,²⁹ which suggested that even one dose of the bivalent HPV vaccine had similarly high efficacy against targeted infections compared to two- or three-doses over the four-year follow-up period. Parallel data on the efficacy and immunogenicity for a single dose of the quadrivalent vaccine are starting to emerge.³⁰ However, two dose schedules are not recommended for those with immune compromising conditions. Recent trials indicate that HPV vaccines are safe and immunogenic in those with HIV using a three dose schedule.^{31–37}

Clinical trials have now established the safety, efficacy and immunogenicity of a three dose schedule of a nonavalent HPV vaccine, whose composition is based on the VLP and vaccine production methods underpinning the quadrivalent vaccine with higher HPV16/18/6 VLP concentrations, more adjuvant and inclusion of the next five most commonly detected oncogenic HPV types in cervical cancers (types 31, 33, 45, 52, 58).^{38–40} For ethical reasons, the control group in the vaccine trial was given the quadrivalent vaccine rather than a placebo. The nonavalent vaccine provided equivalent antibody titres against HPV16/18/6/11 as the quadrivalent vaccine at month 7 and recipients had an equivalent incidence of 6/11/16/18-related infection and high grade cervical disease (CIN2+) rates. In the per-protocol efficacy population (uninfected at baseline), the vaccine provided significant efficacy against persistent infection (risk reduction 96.0% (95%CI 94.4–97.2%)) and high grade cervical disease (96.3% (95%CI 79.5–99.8%)) due to the added protection against HPV31/33/45/52/58. Injection site reactions were more frequent in nonavalent vaccine recipients (90.7% *vs.* 80.9%).³⁸

Positioning the Value of New HPV Vaccines: The Nonavalent Vaccine and Beyond

Now that the nonavalent vaccine is licensed, vaccine purchasers are faced with a choice of three vaccines: bivalent, quadrivalent and nonavalent, each with different price points. Understanding their relative value is vital for optimal national recommendations and procurement decisions. Economic models of HPV vaccination are needed to inform this process, but published cost-effectiveness evaluations of the nonavalent vaccine are currently limited to Canada⁴¹, US⁴², Kenya and Uganda,⁴³ and vaccine costs can rapidly change.

A key determinant of the incremental value of the nonavalent vaccine compared with previous HPV vaccines is the relative contribution of high-risk HPV types besides HPV 16 and 18 to HPV-related cancers and cancer precursors. These HPV types contribute little to anal, oropharyngeal, penile, vulvar and vaginal cancer,⁴⁴ so protection against cervical cancer and its precursors is by far the most important incremental benefit of nonavalent vaccination. A large meta-analysis of HPV-type distribution in HPV-positive women across the spectrum of cervical disease showed that high-risk types other than HPV16 and 18 account for important proportions of HPV-positive CIN2 and CIN3, but their contribution dropped in invasive cervical cancer.⁴⁵ Another study suggests that HPV types in the nonavalent vaccine together account for 89.4% of cervical cancers worldwide, compared with 70.8% for HPV 16 and 18 alone.⁴⁶ Analysis of the placebo arms of the quadrivalent HPV vaccine trial suggests that over 85% of CIN3 lesions, 70–80% of CIN2 lesions and about half of CIN1 are caused by the types included in the nonavalent vaccine.⁴⁷

Yet a trial of the bivalent vaccine in 14 countries demonstrated 93.2% reduction of CIN3+ lesions irrespective of HPV type, which could be attributed to strong vaccine cross-

protection against high-risk HPV types not in the vaccine.⁴⁸ However, the study only showed results for trial participants followed up for four years, which complicates interpretation of potential cancer prevention. First, it is unclear if cross-protective immunity will last.⁴⁹ Second, non-vaccine high-risk HPV types take longer to progress to CIN3+ lesions compared with HPV 16 and 18⁵⁰ and the majority of CIN3+ lesions prevented were 16 or 18 related.

An alternative approach to project potential vaccine impact against cervical cancer is to apply vaccine efficacy against persistent infection to estimate cancer reduction. This approach has been used by several modelling studies^{51,52} and using this approach the nonavalent vaccine is projected to prevent a much greater proportion of cervical cancers than the bivalent or quadrivalent vaccines. A Canadian study suggested that the nonavalent vaccine could be priced about \$CAN11 (\$CAN4-\$18) higher (about 10% higher per dose) than the quadrivalent vaccine and still be considered more cost effective.⁴¹ A similar study, predicted that, at a price of \$13 more than the quadrivalent (9% more) per dose, the nonavalent would be cost-saving in the U.S.⁴²

Several countries have adopted two-dose vaccine schedules using bivalent or quadrivalent vaccine. The nonavalent vaccine is currently licensed only with a three-dose schedule, although two dose immunogenicity studies are in progress.⁵³

Utility of Screening in the New Era of Vaccines

In most of the developed world, cervical cancer screening by routine cytology has proven effective in reducing cervical cancer burden.⁵⁴ The availability of prophylactic HPV vaccines will challenge many countries to revise their cervical cancer prevention programs to integrate screening and vaccination. Similar to the considerations raised above, the utility of screening vaccinated populations is directly related to the proportion of cancers predicted to be prevented by the vaccination program, which are dictated by the type of vaccine used and the population level vaccine coverage over time. Because these factors will vary over time and between countries, we discuss the utility of screening under four general scenarios: (i) high income country (HIC) with organized national HPV immunization (high coverage) and screening programs, (ii) HIC with opportunistic immunization (variable coverage) and screening, (iii) middle income country (MIC) with national immunization program and ineffective national screening program, and (iv) low income country (LIC) with no immunization or screening program.

In the two HIC scenarios, there are challenges inherent in making a single integrated screening recommendation based on vaccination, since the screen-eligible populations will have a significant mix of both vaccinated and unvaccinated women. For example, in Denmark (a country representative of scenario 1), no more than half of the screen-eligible population (ages 21–65 years) will have been vaccinated by 2029, and a fully vaccinated cohort would not occur until around 2060.⁵⁵ The situation will only be exacerbated in the second

HIC scenario, which is typified by the United States with a relatively low (<40% female three dose)¹⁶ and variable vaccine coverage.^{56,57} Therefore, while screening cannot be discontinued in the foreseeable future in these scenarios, the epidemiology of cervical cancer and pre-cancer will evolve in an age-dependent manner as the vaccinated populations mature. The impact will be most profound on the incidence of CIN3, the primary target of screening. Based on the attributable fractions of CIN3 caused by HPV16/18, in cohorts vaccinated with bivalent or quadrivalent vaccine, CIN3 rates could be reduced up to 70% in women under age 30 years.^{58–60} The degree of overall reduction is expected to be lower (~50%) in women aged 30 and older, as other less-oncogenic types cause a larger proportion of the disease burden at older ages.⁶¹ In Australia, rates of CIN3 are already declining in young women, halving in those under 20 and falling by 21% in those 20–24 years by 2012, 5 years after HPV vaccine implementation.⁶²

Thus, when considering bivalent or quadrivalent vaccinated populations, the residual risk of cancer remains sufficiently high to make elimination of screening undesirable. The primary goal of integrated vaccination and screening in these scenarios is to implement changes to screening programs which increase the efficiency and cost-effectiveness without a significant detriment to sensitivity. Options include increasing the age to initiate screening, given the extremely low rate of non-HPV16/18 positive CIN3 lesions in younger women, and increasing the interval between normal screens in vaccinated cohorts.^{63,64} Primary screening with HPV DNA testing followed by appropriate triage (*e.g.*, cytology or molecular markers such as HPV genotyping, p16/Ki67, or methylation⁶⁵) offer potential alternatives to current screening algorithms to meet these requirements. When considering nonavalent vaccinated populations, the residual CIN3 and cancer risk will be low (~10% of unvaccinated populations).⁶¹ Further work is needed to evaluate the balance of costs of continued screening in a population vaccinated with nonavalent vaccine at high coverage against an increasingly low risk of cervical cancer.

More practical considerations prevail when considering the utility of screening in the MIC and LIC settings. The costs of current combinations of HPV vaccination and screening in the HIC scenarios are very high, *e.g.*, around \$10 billion per year in the US.⁶⁶ In MIC and LIC settings, this high cost is simply not feasible. In LMIC with national immunization programs and ineffective national screening programs, the near term decision is whether and how much to invest in improvements in screening. The transition time to a fully vaccinated screening population is similar in these countries, and thus it is reasonable to try to identify an affordable and effective screening strategy to avoid continued high rates of cervical cancer for another half century. As recommended by the WHO, screening using HPV-based tests is preferred to a more subjective morphology-based screen (*eg.*, VIA or cytology). At the present time, costs of HPV assays

remain prohibitively expensive in many LMICs, though with expiring patents and competition this may represent only a temporary barrier to implementation.⁶⁷ If the countries with national immunization programs with high coverage (e.g., Bhutan, Malaysia, Rwanda) were to transition to nonavalent vaccination, it may be feasible to phase out screening in vaccinated cohorts altogether in the future. In LIC with no screening or immunization program and extremely limited financial resources, integrated screening and vaccination programs will likely be unaffordable. More work on the cost-effectiveness of once or twice in a lifetime screening using screen-and-treat strategies *versus* vaccination in these scenarios will be important^{43,68}, but will most likely be driven by costs of screening tests and vaccine, as well as the infrastructure requirements and costs for each program.⁶⁸

Impact of HPV Vaccine on Cancers Other Than Cervical Cancer

Research in the field of HPV has traditionally been focused on cervical infection and related cancers, mainly because cervical cancers account for an estimated 87% of all HPV-attributable cancers worldwide (92% in Low to Middle Income Countries and 64% in High Income Countries (HIC)).⁶⁹ Reasons for shifting attention to HPV-attributable non-cervical cancers include the reported increase in the incidence of oropharyngeal and anal cancers in the US and some other HIC^{69,70}, and recent results showing that HPV vaccines are highly effective at preventing persistent HPV infection and pre-cancerous lesions in sites other than the cervix.^{8,71–75} HIV-infected people are a population especially vulnerable to HPV-induced cancers. Among people living with HIV in the US, 10% of incident cancers are caused by HPV infection, with two thirds of these cases being anal cancer in men.⁷⁶

Examining the potential population-level impact of current prophylactic HPV vaccination on non-cervical cancers is particularly important given the absence of evidence-based screening programs for these cancers. Key research questions include: (i) what will be the impact of HPV vaccination on non-cervical cancers and (ii) when will these benefits occur? Epidemiological and economic models are increasingly being used to examine such questions as clinical efficacy trials are often limited in duration and scope (e.g., they do not capture herd effects).⁷⁷

A recent transmission-dynamic modelling analysis predicted that prophylactic HPV vaccination can substantially reduce the burden of non-cervical HPV-related cancers in HIC.⁴² Assuming lifelong vaccine efficacy, the model predicted that vaccination with the nonavalent vaccine can reduce non-cervical HPV-attributable cancers in the U.S. by 80%–84% over 70 years, which would lead to about 300,000 cancers averted and \$12,000 million in healthcare costs saved in this timeframe.⁴² The model estimated that one non-cervical HPV-related cancer would be prevented for every 420 vaccinated individuals. Modeling analysis from the U.S., Canada and U.K., also suggest that the prevention of non-

cervical cancers would represent about 30–40% of health gains from prophylactic HPV vaccination.^{26,42,77–79} However, given the older median age at cancer diagnosis (58–68 years for non-cervical cancers vs. 48 years for cervical cancers)⁸⁰, the benefits of HPV vaccination on non-cervical sites will take significantly longer to realize. Finally, there is expected to be very little difference between the bivalent, quadrivalent and nonavalent HPV vaccines in non-cervical cancer prevention, given that HPV-16 is present in >85% of these cancers.⁶⁹

HPV and Head and Neck Cancer, Work in Progress

HPV is responsible for a rising incidence of oropharyngeal cancers (OPCs) in the US and in other HIC.^{81,82} These incidence trends are most notable in younger age cohorts and men.^{81,83} In the US, approximately 70–80% of OPCs, which include base of tongue and tonsil cancers, are attributed to HPV infection and the incidence of OPC is projected to exceed the incidence of cervical cancer by 2025.⁸²

Given the increase in HPV-driven OPCs, primary prevention is ideal. Prophylactic HPV vaccines are expected to protect against the majority of biologically-relevant oral HPV infections (mainly HPV16) that could lead to HPV-driven OPC.⁷⁴ Yet, an important public health question is whether the current vaccine strategies, which aim to vaccinate adolescents with the goal of protecting against anogenital HPV infection and its associated diseases acquired after sexual debut⁸⁴, will have the necessary duration of protection to provide lifelong protection against oral HPV infections. Understanding when the infections that lead to HPV-driven OPC are acquired is now a critical question.⁸⁵

For currently unvaccinated cohorts, early detection of HPV-driven OPC is an appealing strategy, if key requirements for evidence-based screening can be met: (i) a highly sensitive and specific screening tool; (ii) diagnostic measures to identify precancerous and/or early staged cancers; (iii) less intensive treatment for the early-stage cancer; (iv) evidence that early detection and treatment reduces cancer-specific mortality; and (v) confirmation that the benefits of screening outweigh the risks. To that end, scientists have investigated an 'oral Pap smear', but with little success.⁸⁶ A candidate biomarker is the HPV16 E6 antibody assay. In a prospective cohort study, HPV16 E6 seropositivity increased risk of OPC >100-fold with notably high specificity (0.5% seroprevalence in controls); the marker was present among OPC cases up to 10 years prior to diagnosis⁸⁷. HPV16 E6 seroprevalence among OPC was similar to published estimates based on tumor DNA at that time,⁸⁸ suggesting that HPV16 E6 seropositivity has a very high sensitivity, approaching 100%, in diagnosing HPV-driven OPCs. This biomarker does not identify the majority of HPV-driven cancers at non-OPC sites, including oral cavity, larynx, cervix, vagina, vulva and penis, although results related to anal cancer may be promising.⁸⁹ However, even with such promising estimates of sensitivity and specificity of HPV16 E6 seropositivity for OPC, these

still may not be sufficiently stringent for a rare cancer. Further work on this marker, in parallel with improved diagnostics of early stage cancers, identification of oropharyngeal precancers, and understanding the risks and benefits of a screening approach for a relatively rare disease, is warranted.⁷³

The presence of HPV in OPC confers a distinct clinical profile from HPV-negative patients.^{90,91} For example, such patients have improved performance status with fewer comorbidities, small primary tumors and larger lymph nodes.⁹² HPV-positive tumor status confers a significant improvement in survival for patients with OPC at primary diagnosis and recurrence.^{92–94} Long-term survival, up to 15 years, has been reported in population-based studies in the US.⁸³ Given the increasing incidence of OPCs in younger individuals with expected long-term survival, current clinical trials have been designed to reduce the long-term sequelae of therapy. These are investigating whether reduced doses of radiation therapy, sparing select patients with chemotherapy or alternate chemotherapeutic choices, and the integration of surgery into the primary treatment algorithm, will improve the quality of life of patients while maintaining the improved survival benefit presently observed in patients with HPV-associated OPC.

In addition, therapeutic HPV vaccines, which elicit cytotoxic T cell responses to eliminate virally-infected cells, are being investigated. If successful, therapeutic vaccines may be of relevance not just for primary treatment, but in the context of secondary prevention. Furthermore, topical delivery of small molecule therapeutic agents for HPV-associated genital infections and precancers have demonstrated efficacy in phase I/II clinical trials and has yet to be explored in head and neck cancers.^{95,96}

Immune checkpoint blockade is a promising, novel treatment which is being explored and growing in popularity in the field of oncology. One immunomodulatory therapy which is actively being evaluated in cancer patients, including HPV-OPC, is immune checkpoint blockade, specifically blockade of the Programmed Cell Death-1 (PD-1) and Programmed Death Ligand-1 (PD-L1) pathway.^{97,98} This therapy focuses on re-activating host immune responses against the cancer cells. Preliminary studies demonstrate its safety and efficacy to reduce tumor burden in head and neck cancer patients with locally recurrent and/or metastatic disease.⁹⁸

With the impetus to design new therapeutic trials, there is controversy regarding the implications of nodal staging, and extracapsular extension, in HPV-OPC⁹⁹ and whether surveillance guidelines and methods should differ by HPV-tumor status.^{100–105}

In summary, the understanding of HPV infection as a cause of OPC, and its implications for prevention and clinical therapy is rapidly evolving. Significant knowledge gaps remain, which provide compelling justification to further study the natural history of oral HPV infection and OPC, vaccine efficacy, prevention and therapeutics.

Future Opportunities and Challenges

Consistent evidence supports the efficacy, effectiveness and safety of HPV vaccines. However, optimal implementation of HPV vaccines remains a considerable challenge. Decreases in vaccination coverage have occurred as a result of targeted anti-vaccination campaigns or trends in social preferences towards vaccination, despite efforts to decrease vaccine prices.

HPV vaccination is perceived by many countries, including HIC, as too expensive and providing delayed benefits. For instance, several countries in the European Union (EU), mainly Eastern European countries, have not yet initiated HPV vaccination programs¹⁰⁶ and, although in most of the EU Member States the vaccine is offered free of charge or reimbursed, the success in terms of coverage of the target groups has been highly variable, ranging from <30% to 80% and over.¹⁰⁷ The determinants of a high uptake of HPV vaccination programs are multifactorial but organized school-based programs¹⁰⁸ usually provide the best coverage and more equitable access to HPV vaccines, followed by organized programs through health-care centres and through general practitioners. Opportunistic programs usually achieve low or ill-defined levels of coverage.

The first national programs in LMIC to achieve high (>90%) coverage were carried out in Rwanda¹⁰⁹ and Bhutan.¹¹⁰ Encouraging progress has been made in lowering the vaccine price. Through public/private negotiations, Gavi has achieved a US \$4.50–\$4.60 per dose price, and >20 Gavi-eligible countries have started vaccinating adolescent girls. The model that has been developed to ensure success is generally a demonstration project prior to full nationwide implementation. Since the cost of delivering the vaccine is estimated to be around US\$5 a course in these setting, the overall cost of vaccinating a girl is probably below US\$15, of which only a fraction is paid by country governments themselves. At these costs, HPV vaccination is potentially affordable in the poorest countries and has been shown to be a cost-effective intervention to introduce.^{111,112}

In non-Gavi eligible countries, the sustainability of the health budget required for HPV vaccination may depend on collective negotiations with vaccine manufacturers.¹¹³ Decision-makers, policy-makers and programme managers should therefore be aware of the wide range of prices (currently \$8.50–100 per dose) for HPV vaccines and the potential to reduce costs by appropriate tendering.

Finally, policy-makers are understandably afraid of investments that take decades to produce fully accountable results. However, the implementation of HPV vaccination programmes is highly feasible compared with that of other cancer prevention strategies, especially in LIC.^{110,114} Cervical cancer screening, for instance, is a more logistically demanding program to implement. It can save individual lives immediately, but in a country starting with no organized cervical cancer prevention programs in place, it can take decades to achieve high coverage and high quality of the entire screening, diagnostic and treatment process.

References

1. Roteli-Martins CM, Naud P, De Borja P, et al. Sustained immunogenicity and efficacy of the HPV-16/18 AS04-adjuvanted vaccine: up to 8.4 years of follow-up. *Hum Vaccin Immunother* 2012; 8:390–97.
2. Ferris D, Samakoses R, Block SL, et al. Long-term study of a quadrivalent human papillomavirus vaccine. *Pediatrics* 2014; 134:e657–65.
3. Schwarz TF, Huang LM, Lin TY, et al. Long-term immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine in 10- to 14-year-old girls: open 6-year follow-up of an initial observer-blinded, randomized trial. *Pediatr Infect Dis J* Dec 2014; 33:1255–61.
4. Schiller JT, Castellsague X, Garland SM. A review of clinical trials of human papillomavirus prophylactic vaccines. *Vaccine* 2012; 30 (Suppl 5):F123–38.
5. Wheeler CM, Castellsagué X, Garland SM, et al. Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. *Lancet Oncol* 2012; 13:100–10.
6. Einstein MH, Takacs P, Chatterjee A, et al. Comparison of long-term immunogenicity and safety of human papillomavirus (HPV)–16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18–45 years: end-of-study analysis of a Phase III randomized trial. *Hum Vaccin Immunother* 2014; 10:3435–45.
7. Brown D, Muller M, Sehr P, et al. Concordance assessment between a multiplexed competitive Luminex immunoassay, a multiplexed IgG Luminex immunoassay, and a pseudovirion-based neutralization assay for detection of human papillomavirus types 16 and 18. *Vaccine* 2014; 32:5880–87.
8. Palefsky JM, Giuliano AR, Goldstone S, et al. HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. *N Engl J Med* 2011; 365:1576–85.
9. Giuliano AR, Palefsky JM, Goldstone S, et al. Efficacy of quadrivalent HPV vaccine against HPV infection and disease in males. *N Engl J Med* 2011; 364:401–11.
10. Klooster TMS, de Ridder, MA Kemmeren JM, et al. Examining a possible association between human papilloma virus (HPV) vaccination and migraine: results of a cohort study in the Netherlands. *Eur J Pediatr* 2015; 174:641–649.
11. Moro PL, Zheteyeva Y, Lewis P, et al. Safety of quadrivalent human papillomavirus vaccine (Gardasil) in pregnancy: adverse events among non-manufacturer reports in the Vaccine Adverse Event Reporting System, 2006–2013. *Vaccine* 2015; 33:519–22.
12. Scheller NM, Svanstrom H, Pasternak B, et al. Quadrivalent HPV vaccination and risk of multiple sclerosis and other demyelinating diseases of the central nervous system. *JAMA* 2015; 313: 54–61.
13. Goss MA, Lievano F, Seminack MM, et al. No adverse signals observed after exposure to human papillomavirus type 6/11/16/18 vaccine during pregnancy: 6-year pregnancy registry data. *Obstet Gynecol* 2014; 123 (Suppl 1):93S
14. Angelo MG, David MP, Zima J, et al. Pooled analysis of large and long-term safety data from the human papillomavirus-16/18-AS04-adjuvanted vaccine clinical trial programme. *Pharmacoeconom Drug Saf* 2014; 23:466–79.
15. Grimaldi-Bensouda L, Guillemot D, Godeau B, et al. Autoimmune disorders and quadrivalent human papillomavirus vaccination of young female subjects. *J Intern Med* 2014; 275:398–408.
16. Stokley S, Jeyarajah J, Yankey D, et al. Human papillomavirus vaccination coverage among adolescents, 2007–2013, and postlicensure vaccine safety monitoring, 2006–2014—United States. *MMWR Morb Mortal Wkly Rep* 2014; 63:620–624.
17. Vichnin M, Bonanni P, Klein NP, et al. An overview of quadrivalent human papillomavirus vaccine safety—2006 to 2015. *Pediatr Infect Dis J* 2015; Sep;34:983–91.
18. ANSM/CNAMTS. Vaccins anti-HPV et risque de maladies auto-immunes : étude pharmacoépidémiologique. Rapport final, Septembre 2015. Available at: <http://ansm.sante.fr/S-informer/Actualite/Vaccination-contre-les-infections-a-HPV-et-risque-de-maladies-auto-immunes-une-etude-Cnamts-ANSM-rassurante-Point-d-information>
19. Global Advisory Committee on Vaccine Safety Statement on the continued safety of HPV vaccination. March 12, 2014 Available at: http://www.who.int/vaccine_safety/committee/topics/hpv/GACVS_Statement_HP_V12_Mar_2014.pdf?ua=1, accessed on March 26, 2015.
20. Drolet M, Benard E, Boily MC, et al. Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis. *Lancet Infect Dis* 2015; 15:565–80.
21. Elfstrom KM, Lazzarato F, Franceschi S, et al. Human papillomavirus vaccination of boys and extended catch-up vaccination: effects on the resilience of programs. *J Infect Dis* 2016; 213: 199–205.
22. World Health Organization. Meeting of the strategic advisory group of experts on immunization, April 2014—conclusions and recommendations. *Wkly Epidemiol Rec* 2014; 89: 221–36.
23. Dobson SR, McNeil S, Dionne M, et al. Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trial. *JAMA* 2013; 309:1793–802.
24. Romanowski B, Schwarz TF, Ferguson LM, et al. Immune response to the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose or 3-dose schedule up to 4 years after vaccination: Results from a randomized study. *Hum Vaccin Immunother* 2014; 10:1155–65.
25. Stanley MA, Sudenga SL, Giuliano AR. Alternative dosage schedules with HPV virus-like particle vaccines. *Expert Rev Vaccines* 2014; 13:1027–38.
26. Jit M, Brisson M, Laprise JF, Choi YH. Comparison of two dose and three dose human papillomavirus vaccine schedules: cost effectiveness analysis based on transmission model. *BMJ* 2015; 350:g7584
27. Romanowski B, Schwarz TF, Ferguson L, et al. Sustained immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine administered as a two-dose schedule in adolescent girls: five-year clinical data and modelling predictions from a randomized study. *Hum Vaccin Immunother* 2016; 12:20–29.
28. Kreimer AR, Struyf F, Del Rosario-Raymundo MR, et al. Efficacy of fewer than three doses of an HPV-16/18 AS04 adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine Trial and the PATRICIA Trial. *Lancet Oncol* 2015; 16:775–86.
29. Kreimer AR, Rodriguez AC, Hildesheim A, et al. Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine. *J Natl Cancer Inst* 2011; 103:1444–1451.
30. Sankaranarayanan R, Prabhu PR, Pawlita M, et al. Immunogenicity and HPV infection after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicenter prospective cohort study. *Lancet Oncol* 2016; 17:67–77.
31. Giacomet V, Penagini F, Trabattani D, et al. Safety and immunogenicity of a quadrivalent human papillomavirus vaccine in HIV-infected and HIV-negative adolescents and young adults. *Vaccine* 2014; 32:5657–61.
32. Kahn JA, Xu J, Kapogiannis BG, et al. Immunogenicity and safety of the human papillomavirus 6, 11, 16, 18 vaccine in HIV-infected young women. *Clin Infect Dis* 2013; 57:735–744.
33. Denny L, Hendricks B, Gordon C, et al. Safety and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine in HIV-positive women in South Africa: a partially-blind randomised placebo-controlled study. *Vaccine* 2013; 31: 5745–5753.
34. Kojic EM, Kang M, Cespedes MS, et al. Immunogenicity and safety of the quadrivalent human papillomavirus vaccine in HIV-1-infected women. *Clin Infect Dis* 2014; 59:127–135.
35. Toft L, Storgaard M, Muller M, et al. Comparison of the immunogenicity and reactogenicity of Cervarix and Gardasil human papillomavirus vaccines in HIV-infected adults: a randomized, double-blind clinical trial. *J Infect Dis* 2014; 209: 1165–1173.
36. Toft L, Tolstrup M, Storgaard M, et al. Vaccination against oncogenic human papillomavirus infection in HIV-infected populations: review of current status and future perspectives. *Sex Health* 2014; 11:511–23.
37. Rainone V, Giacomet V, Penagini F, et al. Human papilloma virus vaccination induces strong human papilloma virus specific cell-mediated immune responses in HIV-infected adolescents and young adults. *Aids* 2015; 29: 739–43.
38. Joura EA, Giuliano AR, Iversen OE, et al. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. *N Engl J Med* 2015; 372:711–23.
39. Luxembourg A, Bautista O, Moeller E, et al. Design of a large outcome trial for a multivalent human papillomavirus L1 virus-like particle vaccine. *Contemp Clin Trials* 2015; 42:18–25.
40. Luxembourg A, Brown D, Bouchard C, et al. Phase II studies to select the formulation of a multivalent HPV L1 virus-like particle (VLP) vaccine. *Hum Vaccin Immunother* 2015; 11: 1313–22.

41. Drolet M, Laprise JF, Boily MC, et al. Potential cost-effectiveness of the nonavalent human papillomavirus (HPV) vaccine. *Int J Cancer* 2014; 134:2264–2268.
42. Brisson M, Laprise J-F, Chesson HW, et al. Health and economic impact of switching from a 4-Valent to a 9-Valent HPV vaccination program in the United States. *J Natl Cancer Inst* 2016; 108:djv282.
43. Kiatpongsan S, Kim JJ. Costs and cost-effectiveness of 9-valent human papillomavirus (HPV) vaccination in two East African countries. *PLoS One* 2014; 9:e106836
44. Parkin DM, Bray F. Chapter 2: The burden of HPV-related cancers. *Vaccine* 2006; 24(Suppl3): S3/11–25.
45. Guan P, Howell-Jones R, Li N, et al. Human papillomavirus types in 115,789 HPV-positive women: a meta-analysis from cervical infection to cancer. *Int J Cancer* 2012; 131:2349–59.
46. Serrano B, Alemany L, Tous S, et al. Potential impact of a nine-valent vaccine in human papillomavirus related cervical disease. *Infect Agent Cancer* 2012; 7:38
47. Joura EA, Ault KA, Bosch FX, et al. Attribution of 12 high-risk human papillomavirus genotypes to infection and cervical disease. *Cancer Epidemiol Biomarkers Prev* 2014; 23:1997–2008.
48. Lehtinen M, Paavonen J, Wheeler CM, et al. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. *Lancet Oncol* 2012; 13:89–99.
49. Malagon T, Drolet M, Boily MC, et al. Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis. *Lancet Infect Dis* 2012; 12:781–89.
50. Kjaer SK, Frederiksen K, Munk C, et al. Long-term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: role of persistence. *J Natl Cancer Inst* 2010; 102:1478–1488.
51. Jit M, Chapman R, Hughes O, et al. Comparing bivalent and quadrivalent human papillomavirus vaccines: economic evaluation based on transmission model. *BMJ* 2011; 343:d5775
52. Van de Velde N, Boily MC, Drolet M, et al. Population-level impact of the bivalent, quadrivalent, and nonavalent human papillomavirus vaccines: a model-based analysis. *J Natl Cancer Inst* 2012; 104:1712–23.
53. A Phase III Study of a 2-dose Regimen of a Multivalent Human Papillomavirus (HPV) Vaccine (V503), Administered to 9 to 14 Year-olds and Compared to Young Women, 16 to 26 years Old (V503-101). Available at: <https://clinicaltrials.gov/ct2/show/NCT01984697>, accessed on August 27, 2015.
54. Peto J, Gilham C, Fletcher O, et al. The cervical cancer epidemic that screening has prevented in the UK. *Lancet* 2004; 364:249–56.
55. Lyng E, Rygaard C, Baillet MV, et al. Cervical cancer screening at crossroads. *APMIS* 2014; 122:667–73.
56. Dunne EF, Stokley S, Chen W, et al. Human papillomavirus vaccination of females in a large health claims database in the United States, 2006–2012. *J Adolesc Health* 2015; 56:408–13.
57. Curtis CR, Dorell C, Yankey D, et al. National human papillomavirus vaccination coverage among adolescents aged 13–17 years—National Immunization Survey—teen, United States, 2011. *MMWR Surveill Summ* 2014; 63 (Suppl 2):61–70.
58. Brotherton JM, Tabrizi SN, Garland SM. Does HPV type 16 or 18 prevalence in cervical intraepithelial neoplasia grade 3 lesions vary by age? An important issue for postvaccination surveillance. *Future Microbiol* 2012; 7:193–99.
59. Baandrup L, Munk C, Andersen KK, et al. HPV16 is associated with younger age in women with cervical intraepithelial neoplasia grade 2 and 3. *Gynecol Oncol* 2012; 124:281–85.
60. Howell-Jones R, Bailey A, Beddows S, et al. Multi-site study of HPV type-specific prevalence in women with cervical cancer, intraepithelial neoplasia and normal cytology, in England. *Br J Cancer* 2010; 103:209–16.
61. Joste NE, Ronnett BM, Hunt WC, et al. Human papillomavirus genotype-specific prevalence across the continuum of cervical neoplasia and cancer. *Cancer Epidemiol Biomarkers Prev* 2015; 24:230–40.
62. Australian Institute of Health and Welfare, Canberra. Cervical screening in Australia 2011–2012. Available at: www.aihw.gov.au/publication-detail/?id=60129546865, accessed on August 28, 2015.
63. Saslow D, Castle PE, Cox JT, et al. American Cancer Society Guideline for Human Papillomavirus (HPV) vaccine use to prevent cervical cancer and its precursors. *CA Cancer J Clin* 2007; 57:7–28.
64. Creighton P, Lew JB, Clements M, et al. Cervical cancer screening in Australia: modelled evaluation of the impact of changing the recommended interval from two to three years. *BMC Public Health* 2010; 10:734
65. Cuzick J, Bergeron C, von Knebel Doeberitz M, et al. New technologies and procedures for cervical cancer screening. *Vaccine* 2012; 30 (Suppl 5):F107–116.
66. Chesson HW, Ekwueme DU, Saraiya M, et al. Estimates of the annual direct medical costs of the prevention and treatment of disease associated with human papillomavirus in the United States. *Vaccine* 2012; 30:6016–19.
67. WHO guidelines for screening and treatment of precancerous lesions for cervical cancer prevention. ISBN 978 92 4 154869 4 (NLM classification: WP 480). (c) World Health Organization 2013.
68. Campos NG, Castle PE, Wright TC, et al. Cervical cancer screening in low-resource settings: A cost-effectiveness framework for valuing trade-offs between test performance and program coverage. *Int J Cancer* 2015; 137:2208–19.
69. Forman D, de Martel C, Lacey CJ, et al. Global burden of human papillomavirus and related diseases. *Vaccine* 2012; 30 (Suppl 5):F12–23.
70. Gillison ML, Alemany L, Snijders PJ, et al. Human papillomavirus and diseases of the upper airway: head and neck cancer and respiratory papillomatosis. *Vaccine* 2012; 30 (Suppl 5): F34–54.
71. Goldstone SE, Jessen H, Palefsky JM, et al. Quadrivalent HPV vaccine efficacy against disease related to vaccine and non-vaccine HPV types in males. *Vaccine* 2013; 31:3849–55.
72. Munoz N, Kjaer SK, Sigurdsson K, et al. Impact of human papillomavirus (HPV)–6/11/16/18 vaccine on all HPV-associated genital diseases in young women. *J Natl Cancer Inst* 2010; 102: 325–39.
73. Gillison ML, Castellsague X, Chaturvedi A, et al. Eurogin Roadmap: comparative epidemiology of HPV infection and associated cancers of the head and neck and cervix. *Int J Cancer* 2014; 134:497–507.
74. Herrero R, Quint W, Hildesheim A, et al. Reduced prevalence of oral human papillomavirus (HPV) 4 years after bivalent HPV vaccination in a randomized clinical trial in Costa Rica. *PLoS ONE* 2013; 8:e68329
75. Lang Kuhs KA, Gonzalez P, Rodriguez AC, et al. Reduced prevalence of vulvar HPV16/18 infection among women who received the HPV16/18 bivalent vaccine: a nested analysis within the Costa Rica Vaccine Trial. *J Infect Dis* 2014; 210:1890–1899.
76. De Martel C, Shiels MS, Franceschi S, et al. Cancers attributable to infections among adults with HIV in the United States. *Aids* 2015; 29: 2173–81.
77. Brisson M, Van de Velde N, Boily MC. Economic evaluation of human papillomavirus vaccination in developed countries. *Public Health Genomics* 2009; 12:343–51.
78. Chesson HW, Ekwueme DU, Saraiya M, Markowitz LE. Cost-effectiveness of human papillomavirus vaccination in the United States. *Emerg Infect Dis* 2008; 14:244–51.
79. Kim JJ, Goldie SJ. Health and economic implications of HPV vaccination in the United States. *N Engl J Med* 2008; 359:821–32.
80. Centers for Disease Control and Prevention (CDC). Human papillomavirus-associated cancers—United States, 2004–2008. *MMWR* 2012; 61:258–61.
81. Chaturvedi AK, Anderson WF, Lortet-Tieulent J, et al. Worldwide trends in incidence rates for oral cavity and oropharyngeal cancers. *J Clin Oncol* 2013; 31:4550–59.
82. Chaturvedi AK, Engels EA, Pfeiffer RM, et al. Human papillomavirus and rising oropharyngeal cancer incidence in the United States. *J Clin Oncol* 2011; 29:4294–301.
83. Chaturvedi AK, Engels EA, Anderson WF, et al. Incidence trends for human papillomavirus-related and -unrelated oral squamous cell carcinomas in the United States. *J Clin Oncol* 2008; 26:612–19.
84. Schiffman M, Castle PE. The promise of global cervical-cancer prevention. *N Engl J Med* 2005; 353:2101–104.
85. Kreimer AR, Pierce Campbell CM, Lin HY, et al. Incidence and clearance of oral human papillomavirus infection in men: the HIM cohort study. *Lancet* 2013; 382:877–87.
86. Fakhry C, Rosenthal BT, Clark DP, et al. Associations between oral HPV16 infection and cytopathology: evaluation of an oropharyngeal “pap-test equivalent” in high-risk populations. *Cancer Prev Res (Phila)* 2011; 4:1378–84.
87. Kreimer AR, Johansson M, Waterboer T, et al. Evaluation of human papillomavirus antibodies and risk of subsequent head and neck cancer. *J Clin Oncol* 2013; 31:2708–15.
88. de Martel C, Ferlay J, Franceschi S, et al. Global burden of cancers attributable to infections in 2008: A review and synthetic analysis. *Lancet Oncol* 2012; 13:607–15.
89. Kreimer AR, Brennan P, Lang Kuhs KA, et al. Human papillomavirus antibodies and future risk of anogenital cancer: a nested case-control study in the European Prospective Investigation

- into Cancer and nutrition study. *J Clin Oncol* 2015; 33:877–84.
90. Gillison ML, D'Souza G, Westra W, et al. Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck cancers. *J Natl Cancer Inst* 2008; 100:407–20.
 91. Gillison ML, Chaturvedi AK, Anderson WF, et al. Epidemiology of human papillomavirus-positive head and neck squamous cell carcinoma. *J Clin Oncol* 2015; 33:3235–42.
 92. Fakhry C, Westra WH, Li S, et al. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. *J Natl Cancer Inst* 2008;100:261–69.
 93. Fakhry C, Zhang Q, Nguyen-Tan PF, et al. Human papillomavirus and overall survival after progression of oropharyngeal squamous cell carcinoma. *J Clin Oncol* 2014; 32:3365–73.
 94. Guo T, Qualliotine JR, Ha PK, et al. Surgical salvage improves overall survival for patients with HPV-positive and HPV-negative recurrent locoregional and distant metastatic oropharyngeal cancer. *Cancer* 2015; 121:1977–84.
 95. Tristram A, Hurt CN, Madden T, et al. Activity, safety, and feasibility of cidofovir and imiquimod for treatment of vulval intraepithelial neoplasia (RT³VIN): a multicentre, open-label, randomised, phase 2 trial. *Lancet Oncol* 2014; 15:1361–68.
 96. Wang JW, Jagu S, Wu WH, et al. Seroepidemiology of human papillomavirus 16 (HPV16) L2 and generation of L2-specific human chimeric monoclonal antibodies. *Clin Vaccine Immunol* 2015; 22:806–16.
 97. Lyford-Pike S, Peng S, Young GD, et al. Evidence for a role of the PD-1:PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma. *Cancer Res* 2013; 73:1733–41.
 98. A Phase IB Multi-Cohort Study of MK-3475 in Patients with Advanced Solid Tumors. ASCO 50th Meeting, June 2014, Chicago, IL.
 99. Lewis JS, Carpenter DH, Thorstad WL, et al. Extracapsular extension is a poor predictor of disease recurrence in surgically treated oropharyngeal squamous cell carcinoma. *Mod Pathol* 2011; 24:1413–20.
 100. Pfister DG, Spencer S, Brizel DM, et al. Head and neck cancers, Version 1.2015. *J Natl Compr Canc Netw* 2015; 13:847–55; quiz 856.
 101. Rettig EM, Wentz A, Posner MR, et al. Prognostic implication of persistent human papillomavirus type 16 DNA detection in oral rinses for human papillomavirus-related oropharyngeal carcinoma. *JAMA Oncol* 2015; 1:907–15.
 102. Dahlstrom KR, Anderson KS, Cheng JN, et al. HPV serum antibodies as predictors of survival and disease progression in patients with HPV-positive squamous cell carcinoma of the oropharynx. *Clin Cancer Res* 2015; 21:2861–69.
 103. Ahn SM, Chan JY, Zhang Z, et al. Saliva and plasma quantitative polymerase chain reaction-based detection and surveillance of human papillomavirus-related head and neck cancer. *JAMA Otolaryngol Head Neck Surg* 2014; 140: 846–54.
 104. Fakhry C, Zhang Q, Nguyen-Tan PF, et al. Reply to B. O'Sullivan et al. *J Clin Oncol* 2015; 33:1708–9.
 105. O'Sullivan B, Adelstein DL, Huang SH, et al. First site of failure analysis incompletely addresses issues of late and unexpected metastases in p16-positive oropharyngeal cancer. *J Clin Oncol* 2015; 33:1707–8.
 106. Seme K, Maver PJ, Korac T, et al. Current status of human papillomavirus vaccination implementation in central and eastern Europe. *Acta Dermatovenerol Alp Pannonica Adriat* 2013; 22: 21–5.
 107. Anttila A, Ronco G, Nicula F, et al. Organization of cytology-based and HPV-based cervical cancer screening. S2. In: Anttila A, Arbyn M, De Vuyst H, Dillner J, Dillner L, Franceschi S, Patnick J, Ronco G, Segnan N, Suonio E, Törnberg S, von Karsa L, eds. European guidelines for quality assurance in cervical cancer screening. Second edition, Supplements. Luxembourg: Office for Official Publications of the European Union, 2015. 69–108.
 108. Brotherton JML. HPV prophylactic vaccines: lessons learned from 10 years experience. *Future Virol* 2015; 10:999–1009.
 109. Binagwaho A, Wagner CM, Gatera M, et al. Achieving high coverage in Rwanda's national human papillomavirus vaccination programme. *Bull World Health Org* 2012; 90:623–8. doi: 10.2471/BLT.11.097253.
 110. Dorji T, Tshomo U, Phuntsho S, et al. Introduction of a National HPV vaccination program into Bhutan. *Vaccine* 2015; 33:3726–30.
 111. Jit M, Brisson M, Portnoy A, et al. Cost-effectiveness of female human papillomavirus vaccination in 179 countries: a PRIME modelling study. *Lancet Glob Health* 2014; 2:e406–14.
 112. Goldie SJ, O'Shea M, Campos NG, et al. Health and economic outcomes of HPV 16,18 vaccination in 72 GAVI-eligible countries. *Vaccine* 2008; 26:4080–93.
 113. van de Vooren K, Curto A, Garattini L. Curing cervical cancer or preventing it: a case of opportunity cost in the long run? *Vaccine* 2014; 32: 6867–69.
 114. Gavi, The Vaccine Alliance. Available at: www.gavi.org, accessed on August 28, 2015.